成纤维细胞活化蛋白
医学
转化研究
癌症研究
癌症
病理
内科学
作者
Liang Zhao,Fei Kang,Yizhen Pang,Jianyang Fang,Long Sun,Hua Wu,Xiaoli Lan,Jing Wang,Haojun Chen
标识
DOI:10.2967/jnumed.123.266983
摘要
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China's engagement with FAPI tracers, aiming to guide future research endeavors.
科研通智能强力驱动
Strongly Powered by AbleSci AI